



Jul 09, 2024

🌐 Albendazole plus Praziquantel versus Albendazole Alone in the Treatment of Neurocysticercosis: A Systematic Review and Meta-Analysis

DOI

<https://dx.doi.org/10.17504/protocols.io.dm6gpzypjlzp/v1>

Luísa Menegaz¹, Gabriela Oliveira Caetano¹, Jade Lingiardi Altoé², Laíse ênin Leodoro Silva¹, Maria Eduarda Silva¹, Artur Menegaz de Almeida¹, Ítalo arros Andrade³, Michele Kreuz MD⁴, Davi Tanajura Costa⁵

¹Federal University of Mato Grosso, Sinop, Brazil; ²Cesumar University, Maringá, Brazil;

³Santo Agostinho University, Vitória da Conquista, Brazil; ⁴Lutheran University of Brazil, Canoas, Brazil;

⁵Federal University of Bahia, Bahia, Brazil



Luísa Menegaz

UFMT

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.dm6gpzypjlzp/v1>

Protocol Citation: Luísa Menegaz, Gabriela Oliveira Caetano, Jade Lingardi Altoé, Laíse ênin Leodoro Silva, Maria Eduarda Silva, Artur Menegaz de Almeida, Ítalo arros Andrade, Michele Kreuz MD, Davi Tanajura Costa 2024. Albendazole plus Praziquantel versus Albendazole Alone in the Treatment of Neurocysticercosis: A Systematic Review and Meta-Analysis.

protocols.io <https://dx.doi.org/10.17504/protocols.io.dm6gpzypjlzp/v1>

License: This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: July 08, 2024

Last Modified: July 09, 2024

Protocol Integer ID: 103037

Keywords: neurocysticercosis, albendazole , praziquantel , treatment of neurocysticercosi, preferred treatment for neurocysticercosi, neurocysticercosi, analysis abstract neurocysticercosi, combination therapy of albendazole, parasitic neurological disease, praziquantel versus albendazole alone, greater benefits than albendazole, albendazole alone, albendazole, neglected tropical disease, tropical diseases in the world, intracranial hypertension, eggs of the taenia solium hatch, praziquantel, taenia solium hatch, headache, seizure, disease

Disclaimer

This research has no financial support.

Abstract

Abstract

Neurocysticercosis is a parasitic neurological disease, considered by the World Health Organization (WHO) as one of the most neglected tropical diseases in the world, also being an important public health concern in Brazil. The eggs of the *Taenia solium* hatch and the larvae spread through highly vascularized tissues, including the brain. Most patients are asymptomatic, but in some cases, cysts can cause inflammation, which can lead to headaches, seizures, and intracranial hypertension. The preferred treatment for neurocysticercosis remains unclear: the combination therapy of albendazole plus praziquantel has been associated with greater benefits than albendazole alone.

Abstract

- 1 Review title:
Albendazole plus Praziquantel versus Albendazole Alone in the Treatment of Neurocysticercosis: A Systematic Review and Meta-Analysis
- 2 PICO:
P - patients with neurocysticercosis;
I - treatment with albendazole and praziquantel associated;
C - placebo, praziquantel alone or with an increased dose or albendazole alone or with an increased dose;
O - complete resolution of the cyst, adverse effects and recurrence of seizures;
T - observational or randomized;
- 3 Exclusion criteria:
alone albendazole or praziquantel used in the intervention group; absence of group control; non-English language; conference abstracts.
- 4 Searches:
We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials from inception to May 11, 2024.
Search strategy: (combined OR combination) AND (praziquantel) AND (albendazole) AND (neurocysticercosis OR "brain cysticercosis").
- 5 Data extraction:
Four authors independently (L.M.V., M.E.S., G.O.C, L.L.L.S.) conducted data extraction, collecting the following information from each study: study population, number of patients, resolution of the cyst or damage, adverse events, seizure relapse and the use of other medications, such as anti-inflammatories and corticosteroids. No data conversion was required.
- 6 Endpoints:
The primary outcome was the resolution of the cyst or lesion. Secondary outcomes included the adverse effects of using the combination, such as headaches and seizure recurrence after treatment. In addition, it was analyzed to consider the use of other medications, like anti-inflammatories and corticosteroids.
- 7 Statistical Analysis::
We used R software version 4.3.2 (R Foundation for Statistical Computing) and the extension package "meta" for all statistical analyses. Studies were eligible for synthesis if



data on each outcome were available. Binary outcomes were analyzed using odds ratio (OR) or risk ratio (RR). Statistical significance was set as p-values < 0,5. Heterogeneity was assessed using I^2 statistics, and significance was attributed to cases with $I^2 > 25\%$. For all outcomes, the Mantel-Haenszel random-effects model was applied.

8 Quality Assessment:

Assessment of risk of bias in individual studies was conducted using the Cochrane Risk of Bias tool for randomized trials. Two independent authors evaluated the bias risk of each study and documented their observations. Disagreements were resolved through discussion and consensus

9 Keywords:

neurocysticercosis, albendazole and praziquantel